Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction

Journal of Psychoactive Drugs
M L PrendergastM Douglas Anglin

Abstract

A number of issues are relevant to the development and use of levo-alpha-acetylmethadol (LAAM) as a treatment alternative to methadone. A brief history of methadone maintenance treatment is provided and variants of standard methadone treatment are discussed. The history and current status of LAAm are discussed, as well as its advantages over methadone. In addition, relevant clinical, research, and policy issues are addressed. LAAm has advantages over methadone specifically with regard to thrice-weekly dosing, potential to reduce HIV/AIDS risk, possible cost savings, and possible improved clinic-community relations. The effective and cost-effective implementation of LAAM as a new treatment for opioid addiction requires attention to a number of issues: (1) LAAM as an HIV prevention measure through its potential risk-reduction effects, (2) the sue of LAAM with specific high-risk subgroups, (3) causes of differential rates of treatment dropout and their amenability to intervention, (4) the role fo patient choice in long-term maintenance treatment, (5) the impact of LAAM on clinic operations, (6) the potential for LAAM as a take-home medication, and (7) the costs of implementing and sustaining LAAM maintenance services.

References

Jan 1, 1978·Annals of the New York Academy of Sciences·J D BlaineJ A Whysner
Jan 10, 1977·JAMA : the Journal of the American Medical Association·E C SenayP F Renault
Oct 1, 1979·The International Journal of the Addictions·M W ParkerF J Willi
Mar 1, 1978·Archives of General Psychiatry·W LingR D Gillis
Jan 1, 1978·The American Journal of Drug and Alcohol Abuse·S B Coleman, J D Kaplan
Jul 1, 1976·The American Journal of Psychiatry·R B ResnickA M Freedman
Aug 1, 1976·The American Journal of Psychiatry·E Karp-GelernterC Savage
Feb 1, 1976·Environmental Health Perspectives·B D Goldstein
Jul 18, 1992·BMJ : British Medical Journal·J Strang, M Farrell
Sep 1, 1991·American Journal of Public Health·S R YancovitzJ W Robinson
Jan 1, 1991·Journal of Substance Abuse Treatment·D M Novick, H Joseph
Jan 1, 1990·Journal of Substance Abuse Treatment·D A CalsynS Lee-Meyer
Sep 20, 1990·The New England Journal of Medicine·D R Gerstein, L S Lewin
Jan 1, 1989·Journal of Substance Abuse Treatment·J L SorensenK Wilkinson
Sep 1, 1988·Journal of Health and Social Behavior·J C BallS R Friedman
Jan 1, 1988·Addictive Behaviors·S MaguraD S Lipton
Jan 1, 1986·Addictive Behaviors·K J Sher, C Descutner
Jan 1, 1986·Journal of Substance Abuse Treatment·F S TennantR Seecof
Jan 1, 1985·Psychopharmacology·T J CrowleyG Zerbe
Oct 1, 1972·JAMA : the Journal of the American Medical Association·J H JaffeS DiMenza
Dec 1, 1973·Preventive Medicine·M W Kampfer
Mar 16, 1970·JAMA : the Journal of the American Medical Association·J H JaffeP H Blachley
May 24, 1971·JAMA : the Journal of the American Medical Association·J H Jaffe, E C Senay
Sep 1, 1983·Neurochemical Research·D A Gibson, A Vernadakis
Dec 1, 1981·Environmental Health Perspectives·B E VaughanD H McKenzie
Nov 1, 1981·Drug and Alcohol Dependence·R R Freedman, G Czertko
Feb 1, 1981·The American Journal of Psychiatry·M MarcoviciJ Kacian
Jan 1, 1995·European Archives of Psychiatry and Clinical Neuroscience·G Bertschy
Aug 1, 1993·The Journal of School Health·K Bosworth, J Sailes

❮ Previous
Next ❯

Citations

Jun 24, 2008·Substance Abuse Treatment, Prevention, and Policy·Lori J Ducharme, Amanda J Abraham
Nov 22, 2015·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Jorge RomeroKevin J Ferrick
Jul 27, 2005·Addiction·Douglas LongshoreRichard A Rawson
May 24, 2000·Drug and Alcohol Dependence·H E JonesS J Heishman
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Alexander N KatchmanSteven N Ebert
Apr 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Tatiana N NanovskayaMahmoud S Ahmed

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.